No black box warning on record for Cotellic

As of the latest FDA labeling reviewed, Cotellic (COBIMETINIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Cotellic medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Review the Full Prescribing Information for vemurafenib for information on the serious risks of vemurafenib. New primary malignancies, cutaneous and non-cutaneous : Monitor patients for new malignancies prior to initiation of therapy, while on therapy, and for up to 6 months following the last dose of COTELLIC. ( 5.1 ) Hemorrhage : Major hemorrhagic events can occur with

No black box warning on record for Cotellic

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Review the Full Prescribing Information for vemurafenib for information on the serious risks of vemurafenib. New primary malignancies, cutaneous and non-cutaneous : Monitor patients for new malignancies prior to initiation of therapy, while on therapy, and for up to 6 months following the last dose of COTELLIC. ( 5.1 ) Hemorrhage : Major hemorrhagic events can occur with

Cotellic Black Box Warning

No black box warning on record for Cotellic

Other warnings & precautions

Cotellic Black Box Warning

No black box warning on record for Cotellic

Other warnings & precautions